UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2013-01, Vol.381 (9863), p.295-302

2013

Link zum Volltext

Verfügbarkeit prüfen

Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-05, Vol.25 (3), p.598-608

2022

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

International journal of clinical oncology, 2015-10, Vol.20 (5), p.905-912

2015

Link zum Volltext

Verfügbarkeit prüfen

Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2004-06, Vol.10 (11), p.3755-3762

2004

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

International journal of clinical oncology, 2021-03, Vol.26 (3), p.578-590

2021

Link zum Volltext

Verfügbarkeit prüfen

Decreased ζ Chain Expression and Apoptosis in CD3+ Peripheral Blood T Lymphocytes of Patients with Melanoma

Clinical cancer research, 2001-03, Vol.7 (3), p.947s-957s

2001

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2019-03, Vol.380 (13), p.1235-1246

2019

Link zum Volltext

Verfügbarkeit prüfen

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

The New England journal of medicine, 2020-09, Vol.383 (11), p.1040-1049

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical Significance of Decreased ζ Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer

Clinical cancer research, 1999-02, Vol.5 (2), p.329-334

1999

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Journal of clinical oncology, 2023-07, Vol.41 (20), p.3595

2023

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer

Clinical cancer research, 1999-06, Vol.5 (6), p.1263-1273

1999

Link zum Volltext

Verfügbarkeit prüfen

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5078-5078

2022

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

European journal of cancer (1990), 2021-09, Vol.154, p.138-146

2021

Link zum Volltext

Verfügbarkeit prüfen

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS200-TPS200

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17076-e17076

2023

Link zum Volltext

Verfügbarkeit prüfen

ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer

Annals of oncology, 2016-11, Vol.27, p.vii106

2016

Link zum Volltext

Verfügbarkeit prüfen

Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.148-148

2023

Link zum Volltext

Verfügbarkeit prüfen

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.326-326

2020

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2022-09, Vol.387 (9), p.860-860

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.90-90

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.15-15

2023

Link zum Volltext

Verfügbarkeit prüfen

Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5079-5079

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(21)
Oncology
(20)
Aged
(15)
Male
(15)
Middle Aged
(15)
Female
(12)
Adult
(11)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Aged, 80 And Over
(8)
Medicine
(8)
Medicine & Public Health
(8)
Prostate Cancer
(8)
Tumors
(8)
Castration
(7)
Androgens
(6)
Patients
(6)
Antineoplastic Agents - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Decreased ζ Chain Expression and Apoptosis in CD3+ Peripheral Blood T Lymphocytes of Patients with Melanoma

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Clinical Significance of Decreased ζ Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE)

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study

ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer

Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study

Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial

Suchergebnisse filtern